Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06335173 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
A Phase 2 study of Alzheimer Disease, sponsored by Acumen Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT06335173: Active Phase 2 study of Alzheimer Disease, sponsored by Acumen Pharmaceuticals.
NCT06335173 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Acumen Pharmaceuticals. The registered enrollment target is 542 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06335173, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Acumen Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Primary Outcome
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The
Conditions Studied
Interventions
- DRUG Placebo
- DRUG sabirnetug
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Bradenton Research Center - Bradenton
- Gil Fernandez-Yera, MD, PA - Coral Gables
- Brain Matters Research - Delray Beach
- Coral Clinical Research - Homestead
- K2 Medical Research - Villages - Lady Lake
- Finlay Medical Research - Miami
- Aqualane Clinical Research - Naples
- Ocala Health - Family Care Specialists - Ocala I - Ocala
- Progressive Medical Research - Port Orange
- Alzheimer's Research and Treatment Center - Stuart - Stuart
- K2 Medical Research - Tampa - Tampa
California
- The Neurology Center of Southern California - Carlsbad - Carlsbad
- Neurology Center of North Orange County - Fullerton
- Irvine Medical Research - Irvine
- Healthy Brain Research - Long Beach
- Syrentis Clinical Research - Santa Ana
- CenExel - California Neuroscience Research Medical Group, Inc (CNR) - Sherman Oaks
Connecticut
- Research Center for Clinical Studies, LLC - Norwalk
District of Columbia
- Re:Cognition Health - Fairfax - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT06335173 still lists
NCT06335173 is an interventional study that assigns participants to a tested intervention. The registered 542 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06335173 names 20 study sites across 4 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06335173 about?
NCT06335173 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)". The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
What is the current status of trial NCT06335173?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2024-02-29. Estimated completion is 2026-10.
What conditions does trial NCT06335173 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06335173?
The interventions under investigation include: Placebo (DRUG), sabirnetug (DRUG).
Who is sponsoring clinical trial NCT06335173?
This trial is sponsored by Acumen Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06335173 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06335173's enrollment target sits among peer trials
542 50th of 306 higher than 257 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI